Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.47 |
| ▸ | TK2 | O00142 | 3/20 | 0.44 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.41 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.41 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.41 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.41 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.39 |
| ▸ | TK1 | P04183 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18512838 | 1.00 | PYGM (0.47) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL28883897 | 1.00 | PYGM (0.47) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL12642452 | 1.00 | PYGM (0.47) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL14885786 | 1.00 | PYGM (0.47) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL15805675 | 1.00 | PYGM (0.47) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL18512840 | 1.00 | PYGM (0.47) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL63879 | 1.00 | PYGM (0.47) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL30381599 | 0.99 | PYGM (0.46) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| Hydrogen Sulfide SCHEMBL28319621 | 0.99 | PYGM (0.46) | PYGMTK2SLC28A1SLC28A2SLC29A1 | |
| SCHEMBL15054378 | 0.93 | P2RY2 (0.46) | PYGMTK2SLC28A1SLC28A2SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790531-B2 | Enzymes and polymerases for the synthesis of RNA | MODERNATX, INC. (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2017-06-22 | — | — | US | disclosed |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | Modema Therapeutics, Inc. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20170130255-A1 | ENZYMES AND POLYMERASES FOR THE SYNTHESIS OF RNA | MODERNATX, INC. (US) | 2017-05-11 | — | — | US | disclosed |
| US-20160354493-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2016-12-08 | — | — | US | disclosed |
| US-20160354492-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-08 | — | — | US | disclosed |
| US-20160348099-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS INC (US) | 2016-12-01 | — | — | US | disclosed |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. | 2016-10-20 | — | — | US | disclosed |
| WO-2015196130-A2 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| WO-2015196118-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2015-12-23 | — | — | WO | disclosed |
| US-9186372-B2 | Split dose administration | MODERNA THERAPEUTICS, INC. (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX, INC. | 2015-10-29 | — | — | US | disclosed |
| WO-2013151672-A2 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | modeRNA Therapeutics (US) | 2013-10-10 | — | — | WO | disclosed |
| US-20130237594-A1 | SPLIT DOSE ADMINISTRATION | modeRNA Therapeutics (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | modeRNA Therapeutics (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160354492-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | PYGM 2621/4885TK2 209/4885SLC28A1 231/4885 |
| US-20160304552-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | PYGM 2621/4885TK2 209/4885SLC28A1 231/4885 |
| US-20130123481-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ADAR, NT5C3B, NSUN2 | PYGM 1594/4885TK2 151/4885SLC28A1 80/4885 |
| US-20160348099-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | PYGM 2621/4885TK2 209/4885SLC28A1 231/4885 |
| US-20170136132-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | PYGM 2038/4885TK2 305/4885SLC28A1 317/4885 |
| US-20130237594-A1 | SPLIT DOSE ADMINISTRATION | IGF2BP1, IGF2BP2, NSUN2 | PYGM 1057/4885TK2 389/4885SLC28A1 674/4885 |
| US-20170175129-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | PYGM 2038/4885TK2 305/4885SLC28A1 317/4885 |
| US-20170136131-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | PYGM 2038/4885TK2 305/4885SLC28A1 317/4885 |
| US-20160354493-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | PYGM 2621/4885TK2 209/4885SLC28A1 231/4885 |
| US-20150307542-A1 | MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, ADAR, NSUN3 | PYGM 2621/4885TK2 209/4885SLC28A1 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.